Investor Relations Corporate Profile Alexion, AstraZeneca Rare Disease is focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. PRESS RELEASES 7/15/21 Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG) 6/11/21 Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021 SEE MORE EVENTS & PRESENTATIONS 04/29/21 at 8:00 AM EDT Alexion Pharmaceuticals, Inc. First Quarter 2021 Results 02/04/21 Alexion Q4 and Full Year 2020 Results SEE MORE